Cargando…
CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets
SIMPLE SUMMARY: A rapidly emerging new approach to treat cancer involves collection of patient immune white blood cells and genetic re-programming of the cells to express a new cancer-detecting receptor called a CAR. This approach has revolutionized the treatment of some blood cancers, whereas solid...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953954/ https://www.ncbi.nlm.nih.gov/pubmed/36831514 http://dx.doi.org/10.3390/cancers15041171 |
_version_ | 1784894006123036672 |
---|---|
author | Maher, John Davies, David M. |
author_facet | Maher, John Davies, David M. |
author_sort | Maher, John |
collection | PubMed |
description | SIMPLE SUMMARY: A rapidly emerging new approach to treat cancer involves collection of patient immune white blood cells and genetic re-programming of the cells to express a new cancer-detecting receptor called a CAR. This approach has revolutionized the treatment of some blood cancers, whereas solid tumours, which account for 90% of all cancers, are proving much more difficult to treat using this approach. A major challenge in this respect relates to the identification of targets that differentiate cancer from healthy cells. In a partner review, we consider clinical data already collected when CAR technology has been applied against solid tumours that express 30 different targets. Here, we explore emerging candidates for which such clinical data are not available yet, but where other data provide information about potential suitability as future clinical targets. ABSTRACT: Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported. Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens. |
format | Online Article Text |
id | pubmed-9953954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99539542023-02-25 CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets Maher, John Davies, David M. Cancers (Basel) Review SIMPLE SUMMARY: A rapidly emerging new approach to treat cancer involves collection of patient immune white blood cells and genetic re-programming of the cells to express a new cancer-detecting receptor called a CAR. This approach has revolutionized the treatment of some blood cancers, whereas solid tumours, which account for 90% of all cancers, are proving much more difficult to treat using this approach. A major challenge in this respect relates to the identification of targets that differentiate cancer from healthy cells. In a partner review, we consider clinical data already collected when CAR technology has been applied against solid tumours that express 30 different targets. Here, we explore emerging candidates for which such clinical data are not available yet, but where other data provide information about potential suitability as future clinical targets. ABSTRACT: Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported. Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens. MDPI 2023-02-11 /pmc/articles/PMC9953954/ /pubmed/36831514 http://dx.doi.org/10.3390/cancers15041171 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Maher, John Davies, David M. CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets |
title | CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets |
title_full | CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets |
title_fullStr | CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets |
title_full_unstemmed | CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets |
title_short | CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets |
title_sort | car-based immunotherapy of solid tumours—a survey of the emerging targets |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953954/ https://www.ncbi.nlm.nih.gov/pubmed/36831514 http://dx.doi.org/10.3390/cancers15041171 |
work_keys_str_mv | AT maherjohn carbasedimmunotherapyofsolidtumoursasurveyoftheemergingtargets AT daviesdavidm carbasedimmunotherapyofsolidtumoursasurveyoftheemergingtargets |